GTC Biotherapeutics (fka GTCB)

[keitern]

GTBC has a vastly superior platform for producing production quantities of a given protein, once it is approved. How competitive is their platform when producing trial quantities?

Conjecture: If it is very expensive to produce trial quantities with GTCB (up front investment in getting the right genes into the goats and developing a process for extracting the protein), potential partners may feel that they will use the cheaper lab for the trial, even knowing they forfeit production efficiency if their drug is eventually approved.